Understanding how microRNA mutations affect cancer risk and treatment
Clinical Validation of the Role of microRNA Binding Site Mutations in Cancer Risk, Prevention and Treatment
This study is looking for people with certain gene mutations to see how they might affect cancer risk and treatment responses.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 15000 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | MiraKind Academic / other |
| Locations | 1 site (Los Angeles, California) |
| Trial ID | NCT02253251 on ClinicalTrials.gov |
What this trial studies
This observational study aims to recruit individuals with specific microRNA binding site mutations, including the KRAS-variant, to explore their association with cancer risk and treatment responses. Participants will provide saliva samples for genetic testing and complete questionnaires about their lifestyle factors. The study seeks to uncover the mechanisms behind these mutations and their impact on health, particularly in relation to cancer and autoimmunity. Results will be shared with participants through their physicians at the conclusion of the study.
Who should consider this trial
Good fit: Ideal candidates include individuals with a personal or family history of cancer, endometriosis, or autoimmunity.
Not a fit: Patients under 18 years old or those who are non-English speaking and unable to provide informed consent may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved cancer risk assessment and personalized treatment strategies for patients with specific genetic mutations.
How similar studies have performed: Other studies have shown promise in understanding genetic mutations related to cancer, but this specific approach focusing on microRNA binding site mutations is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Personal or family history of cancer * Personal history of endometriosis, or autoimmunity Exclusion Criteria: * Younger than 18 * Non-english speaking and unable to understand and sign the consent
Where this trial is running
Los Angeles, California
- MiraKind — Los Angeles, California, United States (Recruiting)
Study contacts
- Principal investigator: Joanne Weidhaas, MDPhD — MiraKind
- Study coordinator: Joanne Weidhaas, MDPhD
- Email: joanne@mirakind.org
- Phone: 203-671-1308
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.